Literature DB >> 14560235

Overexpression of mutated IkappaBalpha inhibits vascular smooth muscle cell proliferation and intimal hyperplasia formation.

Brian S Zuckerbraun1, Carol A McCloskey, Raja S Mahidhara, Peter K M Kim, Bradley S Taylor, Edith Tzeng.   

Abstract

PURPOSE: Vascular injury and inflammation are associated with elaboration of a number of cytokines that signal through multiple pathways to act as smooth muscle cell (SMC) mitogens. Activation of the nuclear factor-kappa B (NF-kappaB) transcription factor is essential for SMC proliferation in vitro and is activated by vascular injury in vivo. Activation of NF-kappaB is controlled by several upstream regulators, including the inhibitors of kappa B (IkappaB). These proteins bind to and keep NF-kappaB inactivated. The purpose of this study was to determine whether adenoviral gene transfer of a mutated IkappaBalpha super-repressor (AdIkappaBalphaSR) could inhibit development of intimal hyperplasia in vivo and to investigate how over-expression of this construct influences in vitro SMC proliferation and cell cycle regulatory proteins.
METHODS: A rat carotid injury model was used to study prevention of intimal hyperplasia. Arteries were assayed 14 days after injury and infection with AdIkappaBalphaSR or adenoviral beta-galactosidase (AdLacZ). Untreated SMC or SMC infected with AdLacZ or AdIkappaBalphaSR were stimulated with 10% fetal bovine serum, interleukin-1beta, or tumor necrosis factor-alpha. Electrophoretic mobility shift assays were used to assay for NF-kappaB activation. Protein levels of IkappaBalpha and cyclin-dependent kinase inhibitors p21(Cip1/Waf1) and p27(Kip1) were determined with Western blot analysis. Proliferation was measured with (3)H-thymidine incorporation assays.
RESULTS: AdIkappaBalphaSR inhibited the development of intimal hyperplasia by 49% (P <.05). Infection with AdIkappaBalphaSR significantly suppressed in vitro SMC proliferation when stimulated with serum, interleukin 1, or tumor necrosis factor alpha, and did not result in cell death. Inhibition of proliferation was associated with increased p21(Cip1/Waf1) and p27(Kip1) protein levels.
CONCLUSIONS: Gene transfer of IkappaBalpha super-repressor inhibited development of intimal hyperplasia in vivo and SMC proliferation in vitro. The antiproliferative activity may be related to cell cycle arrest through upregulation of the cyclin-dependent kinase inhibitors p21 and p27. Overexpression of IkappaBalpha may be a future therapeutic option in treatment of vascular diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14560235     DOI: 10.1016/s0741-5214(03)00427-0

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  15 in total

1.  C-peptide reduces pro-inflammatory cytokine secretion in LPS-stimulated U937 monocytes in condition of hyperglycemia.

Authors:  Jaime Haidet; Vincenza Cifarelli; Massimo Trucco; Patrizia Luppi
Journal:  Inflamm Res       Date:  2011-09-27       Impact factor: 4.575

2.  A20 inhibits post-angioplasty restenosis by blocking macrophage trafficking and decreasing adventitial neovascularization.

Authors:  Scott M Damrauer; Mark D Fisher; Hiromi Wada; Jeffrey J Siracuse; Cleide G da Silva; Karam Moon; Eva Csizmadia; Elizabeth R Maccariello; Virendra I Patel; Peter Studer; Sanah Essayagh; William C Aird; Soizic Daniel; Christiane Ferran
Journal:  Atherosclerosis       Date:  2010-04-04       Impact factor: 5.162

3.  Construction of NF-κB-targeting RNAi adenovirus vector and the effect of NF-κB pathway on proliferation and apoptosis of vascular endothelial cells.

Authors:  Gang Chen; Yufang Qiao; Jin Yao; Qiqin Jiang; Xu Lin; Feng Chen; Fenghui Lin; Miao Lin; Lixiang Lin; Pengli Zhu
Journal:  Mol Biol Rep       Date:  2010-02-03       Impact factor: 2.316

4.  Resveratrol at high doses acts as an apoptotic inducer in endothelial cells.

Authors:  Kyungmin In; Jongbong Park; Heonyong Park
Journal:  Cancer Res Treat       Date:  2006-02-28       Impact factor: 4.679

5.  Ablation of NF-kappaB expression by small interference RNA prevents the dysfunction of human umbilical vein endothelial cells induced by high glucose.

Authors:  Gang Chen; Xiaoyan Shen; Jin Yao; Feng Chen; Xu Lin; Yufang Qiao; Tingting You; Fenghui Lin; Xiaowen Fang; Xin Zou; Lixiang Lin
Journal:  Endocrine       Date:  2008-11-08       Impact factor: 3.633

6.  Vinpocetine suppresses pathological vascular remodeling by inhibiting vascular smooth muscle cell proliferation and migration.

Authors:  Yujun Cai; Walter E Knight; Shujie Guo; Jian-Dong Li; Peter A Knight; Chen Yan
Journal:  J Pharmacol Exp Ther       Date:  2012-08-22       Impact factor: 4.030

7.  Comprehensive gene expression profiling reveals synergistic functional networks in cerebral vessels after hypertension or hypercholesterolemia.

Authors:  Wei-Yi Ong; Mary Pei-Ern Ng; Sau-Yeen Loke; Shalai Jin; Ya-Jun Wu; Kazuhiro Tanaka; Peter Tsun-Hon Wong
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

8.  Increased protein O-GlcNAc modification inhibits inflammatory and neointimal responses to acute endoluminal arterial injury.

Authors:  Dongqi Xing; Wenguang Feng; Laszlo G Nöt; Andrew P Miller; Yun Zhang; Yiu-Fai Chen; Erum Majid-Hassan; John C Chatham; Suzanne Oparil
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-09       Impact factor: 4.733

9.  Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis.

Authors:  Claudia Monaco; Evangelos Andreakos; Serafim Kiriakidis; Claudia Mauri; Colin Bicknell; Brian Foxwell; Nicholas Cheshire; Ewa Paleolog; Marc Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-02       Impact factor: 11.205

10.  Pyrrolidine dithiocarbamate restores endothelial cell membrane integrity and attenuates monocrotaline-induced pulmonary artery hypertension.

Authors:  Jing Huang; Pawel M Kaminski; John G Edwards; Albert Yeh; Michael S Wolin; William H Frishman; Michael H Gewitz; Rajamma Mathew
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-04-04       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.